The Asia Pacific IVD In Cardiology And Neurology Market would witness market growth of 10.2% CAGR during the forecast period (2023-2030).
The China market dominated the Asia Pacific IVD In Cardiology And Neurology Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,031.7 million by 2030. The Japan market is registering a CAGR of 9.4% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 10.9% during (2023 - 2030).
IVD trends have been influenced by the growing prevalence of telemedicine and remote patient monitoring. Home-based diagnostic tests, especially cardiology, enable patients to monitor key biomarkers and share real-time data with healthcare providers. This trend enhances patient engagement, facilitates timely interventions, and contributes to a more comprehensive approach to healthcare delivery.
Additionally, telemedicine enables real-time data sharing between patients and healthcare providers. Home-based diagnostic devices often have connectivity features, allowing patients to transmit test results and vital signs directly to their healthcare teams. In cardiology, real-time data sharing is valuable for monitoring dynamic cardiovascular parameters, allowing healthcare providers to assess a patient's condition remotely and intervene promptly if necessary.
Cardiovascular diseases, such as cardiovascular disease itself, have emerged as the primary contributors to both morbidity and mortality in Australia. As per the data from the Government of Australia, an estimated 571,000 Australians aged 18 or older (2.9% of the adult population) had coronary heart disease in 2020-21. An estimated 56,700 individuals aged 25 and older experienced an acute coronary event in 2020, such as a myocardial infarction or unstable angina; this equates to approximately 155 incidents per day. Thus, the rising number of heart disease cases and the expansion of the healthcare sector in the Asia Pacific are expected to boost the demand for In vitro diagnostics in cardiology and neurology.
Based on Product Type, the market is segmented into Reagents & Consumables, Instruments, and Software & Services. Based on End Use, the market is segmented into Hospitals, Clinical Laboratories, and Others. Based on Technology, the market is segmented into Immunoassays, Molecular Diagnostics, Hematology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific IVD In Cardiology And Neurology Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,031.7 million by 2030. The Japan market is registering a CAGR of 9.4% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 10.9% during (2023 - 2030).
IVD trends have been influenced by the growing prevalence of telemedicine and remote patient monitoring. Home-based diagnostic tests, especially cardiology, enable patients to monitor key biomarkers and share real-time data with healthcare providers. This trend enhances patient engagement, facilitates timely interventions, and contributes to a more comprehensive approach to healthcare delivery.
Additionally, telemedicine enables real-time data sharing between patients and healthcare providers. Home-based diagnostic devices often have connectivity features, allowing patients to transmit test results and vital signs directly to their healthcare teams. In cardiology, real-time data sharing is valuable for monitoring dynamic cardiovascular parameters, allowing healthcare providers to assess a patient's condition remotely and intervene promptly if necessary.
Cardiovascular diseases, such as cardiovascular disease itself, have emerged as the primary contributors to both morbidity and mortality in Australia. As per the data from the Government of Australia, an estimated 571,000 Australians aged 18 or older (2.9% of the adult population) had coronary heart disease in 2020-21. An estimated 56,700 individuals aged 25 and older experienced an acute coronary event in 2020, such as a myocardial infarction or unstable angina; this equates to approximately 155 incidents per day. Thus, the rising number of heart disease cases and the expansion of the healthcare sector in the Asia Pacific are expected to boost the demand for In vitro diagnostics in cardiology and neurology.
Based on Product Type, the market is segmented into Reagents & Consumables, Instruments, and Software & Services. Based on End Use, the market is segmented into Hospitals, Clinical Laboratories, and Others. Based on Technology, the market is segmented into Immunoassays, Molecular Diagnostics, Hematology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Thermo Fisher Scientific, Inc.
- F.Hoffmann-La Roche Ltd.
- Sysmex Corporation
- Siemens Healthineers AG (Siemens AG)
- Quest Diagnostics Incorporated
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Danaher Corporation (Beckman Coulter, Inc.)
- Becton, Dickinson and Company
- Natera, Inc.
Market Report Segmentation
By Product Type- Reagents & Consumables
- Instruments
- Software & Services
- Hospitals
- Clinical Laboratories
- Others
- Immunoassays
- Molecular Diagnostics
- Hematology
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific IVD In Cardiology And Neurology Market by Product Type
Chapter 5. Asia Pacific IVD In Cardiology And Neurology Market by End-use
Chapter 6. Asia Pacific IVD In Cardiology And Neurology Market by Technology
Chapter 7. Asia Pacific IVD In Cardiology And Neurology Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- Sysmex Corporation
- Siemens Healthineers AG (Siemens AG)
- Quest Diagnostics Incorporated
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- Danaher Corporation (Beckman Coulter, Inc.)
- Becton, Dickinson and Company
- Natera, Inc.
Methodology
LOADING...
